Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Lifted by AlphaQuest LLC

AlphaQuest LLC lifted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 116.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,020 shares of the company's stock after purchasing an additional 1,622 shares during the quarter. AlphaQuest LLC's holdings in Krystal Biotech were worth $473,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Krystal Biotech in the third quarter worth $40,000. Huntington National Bank grew its holdings in Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company's stock worth $104,000 after acquiring an additional 283 shares during the period. KBC Group NV grew its holdings in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company's stock worth $117,000 after acquiring an additional 132 shares during the period. Avanza Fonder AB acquired a new position in Krystal Biotech during the fourth quarter worth about $119,000. Finally, Blue Trust Inc. grew its holdings in Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after acquiring an additional 433 shares during the period. Institutional investors own 86.29% of the company's stock.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company's stock.

Krystal Biotech Stock Down 3.5 %

NASDAQ:KRYS opened at $178.39 on Thursday. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of 59.66 and a beta of 0.87. The stock has a fifty day simple moving average of $162.66 and a 200 day simple moving average of $174.19.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period last year, the company posted $0.30 EPS. The business's quarterly revenue was up 116.4% compared to the same quarter last year. Equities analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Analyst Ratings Changes

KRYS has been the topic of a number of research analyst reports. Citigroup lifted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and set a $221.00 target price on shares of Krystal Biotech in a report on Friday, February 28th. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and an average target price of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.